Columbia Laboratories Inc.
354 Eisenhower Parkway
Plaza One Second Floor
Livingston,
NJ 07039
United States - Map
Phone: 866-566-5636
Fax: 866-994-3001
Web Site: http://www.columbialabs.com
| Columbia Laboratories, Inc. engages in the research, development, and commercialization of womens healthcare and endocrinology products. Its products are used to treat infertility, endometriosis, dysmenorrhea, preterm birth for women with a short cervix at mid-pregnancy, and hormonal deficiencies. The companys products primarily utilize its patented Bioadhesive Delivery System technology. The company markets vaginal progesterone gel products to assist women who are infertile become pregnant in the United States, which include CRINONE 8% for technical procedures to reproductive endocrinologists; PROCHIEVE 8% to obstetricians and gynecologists; and PROCHIEVE 4% for treatment of secondary amenorrhea. It also provides vaginal gel womens products, such as Replens, a vaginal moisturizer for replenishment of vaginal moisture; RepHresh vaginal gel that eliminates vaginal odor; and Advantage-S, a female contraceptive gel. In addition, the company offers STRIANT, a testosterone buccal system for the treatment of hypogonadism in men; and Advance Formula Legatrin PM for the relief of occasional pain and sleeplessness associated with minor muscle aches. Further, it engages in clinical development activities of vaginally-administered lidocaine to prevent and treat dysmenorrhea, as well as vaginally-administered carbamide peroxide for treating vaginal infections; and testosterone progressive hydration vaginal tablet for women, which completed phase I trial. The company was founded in 1986 and is based in Livingston, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Robert S. Mills , 56
Chief Exec. Officer, Pres |
N/A
| N/A | Mr. Michael McGrane , 59
Sr. VP, Sec. and Gen. Counsel |
N/A
| N/A | Mr. Lawrence A. Gyenes , 58
Chief Financial Officer, Sr. VP and Treasurer |
N/A
| N/A | Ms. Amy Raskopf ,
Mang. of Investor Relations |
N/A
| N/A | Mr. Paul B. Schwartz ,
Exec. Director of Licensing & Bus. Devel. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.14% Nasdaq 0.00%
Profile
